Delivery of a healthy baby after first-trimester maternal exposure to lapatinib

Clinical Breast Cancer

Volumn 7, Issue 4, 2006, Pages 339-341

  Kelly, Hanna ^a   Graham, Mark ^b   Humes, Elizabeth ^a   Dorflinger, Laneta J ^c   Boggess, Kim A ^d   O'Neil, Bert H ^a   Harris, Jennifer ^e   Spector, Neil L ^e   Dees, E Claire ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b Waverly Hematology Oncology   (United States)

^c FAMILY HEALTH INTERNATIONAL   (United States)

^d UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^e GLAXOSMITHKLINE   (United States)

Author keywords

Drug therapy; Epidermal growth factor receptor; HER2 neu

Indexed keywords

CHORIONIC GONADOTROPIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUOROURACIL; LAPATINIB; NAVELBINE; PACLITAXEL; TAMOXIFEN; TRASTUZUMAB;

ADULT; AMENORRHEA; ARTICLE; BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CASE REPORT; CHILDBIRTH; CONCEPTION; CONDOM; CONTRACEPTION; DIARRHEA; DRUG ERUPTION; DRUG UTILIZATION; DRUG WITHDRAWAL; EMBRYO DEVELOPMENT; FEMALE; FETUS DEATH; FIRST TRIMESTER PREGNANCY; GENE OVEREXPRESSION; HUMAN; MASTECTOMY; METASTASIS POTENTIAL; PERINATAL DRUG EXPOSURE; PREGNANCY; PROBABILITY; SECOND TRIMESTER PREGNANCY; TERATOGENICITY; THORAX WALL CANCER; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 33750848163     PISSN: 15268209     EISSN: None     Source Type: Journal    
DOI: 10.3816/CBC.2006.n.048     Document Type: Article

References (23)

1. Burris HA, Hurwitz HI, Dees EC, et al. Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. J Clin Oncol 2005; 23:5305-5313.
2. Romond EH, Perez EA, Bryant J, et al. Doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab as adjuvant therapy for patients with HER-2 positive operable breast cancer. Presented at the Annual Meeting of the American Society of Clinical Oncology; May 13-17, 2005; Orlando, FL. Available at http://www.asco.org/ac/ 1,1003,_12-002514-00_18-0034-00_19-00934-00_21-001,00.asp. Accessed August 18, 2005.
3. Perez EA, Suman VJ, Davidson N, et al. NCCTG N9831 May 2005 update. Presented at the Annual Meeting of the American Society of Clinical Oncology; May 13-17, 2005; Orlando, FL. Available at http://www.asco.org/ ac/1,1003,_12-002514-00_18-0034-00_19-00934-00_21-001,00.asp. Accessed August 18, 2005.
4. Piccart-Gebhart MJ. First results of the HERA trial. Presented at the Annual Meeting of the American Society of Clinical Oncology; May 13-17, 2005; Orlando, FL. Available at http://www.asco.org/ac/ 1,1003,_12-002514-00_18-0034-00_19-00934-0021-001,00.asp. Accessed August 18, 2005.
5. Watson WJ. Herceptin (trastuzumab) therapy during pregnancy: association with reversible anhydramnios. Obstet Gynecol 2005; 105:642-643.
6. Gywn K, Theriault RL. Breast cancer during pregnancy. UpToDate version 13.0. Available at: www.uptodate.com. Accessed May 10, 2005.
7. Berry DL, Theriault RL, Holmes FA, et al. Management of breast cancer during pregnancy using a standardized protocol. J Clin Oncol 1999; 17:855-861.
8. Gywn K, Theriault RL. Breast cancer during pregnancy. Oncology 2001; 15:39-46.
9. Ebert U, Löffler H, Kirch W. Cytotoxic therapy and pregnancy. Pharmacol Ther 1997; 74:207-220.
10. Gonzalez-Angulo AM, Walters RS, Carpenter RJ Jr, et al. Paclitaxel chemotherapy in a pregnant patient with bilateral breast cancer. Clin Breast Cancer 2004; 5:317-319.
11. De Santis M, Lucchese A, De Carolis S, et al. Metastatic breast cancer in pregnancy: first case of chemotherapy with docetaxel. Eur J Cancer Care (Engl) 2000; 9:235-237.
12. Miettinen PJ, Chen JR, Shum L, et al. Epidermal growth factor receptor function is necessary for normal craniofacial development and palate closure. Nat Genet 1999; 22:69-73.
13. Miettinen PJ, Berger JE, Meneses J, et al. Epithelial immaturity and multiorgan failure in mice lacking epidermal growth factor receptor. Nature 1995; 376:337-341.
14. Yoshimura S, Masuzaki H, Miura E, et al. Effect of epidermal growth factor on lung growth in experimental fetal pulmonary hypoplasia. Early Hum Dev 2000; 57:61-69.
15. Burrows RC, Wancio D, Levitt P, et al. Response diversity and the timing of progenitor cell maturation are regulated by developmental changes in EGFR expression in the cortex. Neuron 1997; 19:251-267.
16. Kee N, McTavish AJ, Papillon J, et al. Receptor protein tyrosine kinases in perinatal developing rat kidney. Kidney Int 1997; 52:309-317.
17. Evian-Brion D, Alsat E. Epidermal growth factor receptor and human fetoplacental development. J Pediatr Endocrinol 1994; 7:295-302.
18. Lee K-F, Simon H, Chen H, et al. Requirement for neuregulin receptor erbB2 in neural and cardiac development. Nature 1995; 378:394-398.
19. Trussell J. Contraceptive failure in the United States. Contraception 2004; 74:89-96.
20. Park J-Y, Su Y-Q, Ariga M, et al. EGF-like growth factors as mediators of LH action in the ovulatory follicle. Science 2004; 303:682-684.
21. Ashkenazi H, Cao X, Motola S, et al. Epidermal growth factor family members: endogenous mediators of the ovulatory response. Endocrinology 2005; 146:77-84.
22. Conti M, Hsieh M, Park JY, et al. Role of the epidermal growth factor network in ovarian follicles. Mol Endocrinol 2006; 20:715-723.
23. Ni J, Ni Y, Wang X, et al. Application of a gene vaccine targeting HER-2/ neu in immunocontraception. DNA Cell Biol 2004; 23:807-814.